<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05123586</url>
  </required_header>
  <id_info>
    <org_study_id>18248</org_study_id>
    <secondary_id>J1V-MC-BT01</secondary_id>
    <secondary_id>2021-001406-30</secondary_id>
    <nct_id>NCT05123586</nct_id>
  </id_info>
  <brief_title>A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Two-Arm, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of LY3361237 as a Treatment for Adults With At Least Moderately Active Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to assess the efficacy and safety of LY3361237 in&#xD;
      participants with at least moderately active systemic lupus erythematosus (SLE). Study will&#xD;
      last up to 34 weeks and may include up to 15 visits.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2021</start_date>
  <completion_date type="Anticipated">August 7, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 17, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Arthritis and/or Rash at Baseline Who Achieve Remission fo Arthritis and/or Rash</measure>
    <time_frame>Week 24</time_frame>
    <description>Percentage of Participants with Arthritis and/or Rash at Baseline Who Achieve Remission of Arthritis and//or Rash</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieve Systemic Lupus Erythematosus Disease Activity Index-4 (SLEDAI-4) Response</measure>
    <time_frame>Week 24</time_frame>
    <description>Percentage of Participants Who Achieve SLEDAI-4 Response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who achieve Systemic Lupus Erythematosus Responder Index-4 (SRI-4 response)</measure>
    <time_frame>Week 24</time_frame>
    <description>Percentage of Participants who achieve SRI-4 response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Steady-state trough serum concentration of LY3361237</measure>
    <time_frame>Week 24</time_frame>
    <description>PK: Steady-state trough serum concentration of LY3361237</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>LY3361237</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are administered LY3361237 subcutaneously (SC) and standard of care (SOC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered SC and SOC given at matching intervals</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3361237</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY3361237</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are diagnosed with SLE at least 24 weeks before Day 1 of study&#xD;
&#xD;
          -  Have documentation of having a score of 10 or more points on the European League&#xD;
             Against Rheumatism (EULAR)/American College of Rheumatology (ACR) 2019 classification&#xD;
             criteria for SLE&#xD;
&#xD;
          -  Have a SLEDAI-2K score ≥6 at screening (Day 1) and clinical Systemic Lupus&#xD;
             Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score ≥4 (not including any&#xD;
             items related to laboratory values) at randomization (Day 2)&#xD;
&#xD;
          -  Must be receiving at least 1 background standard-of-care medication for SLE&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants are excluded if they have received any of the following medications or&#xD;
             therapies within the indicated timeframe prior to the randomization visit (Day 2).&#xD;
&#xD;
          -  Are currently receiving oral corticosteroids at doses &gt;20 mg per day of prednisone (or&#xD;
             equivalent) or have adjusted the dosage of corticosteroids within 2 weeks before&#xD;
             starting study treatment&#xD;
&#xD;
          -  Have received parenteral corticosteroids within 12 weeks before starting study&#xD;
             treatment or are expected to require parenteral corticosteroids during the study&#xD;
&#xD;
          -  Have a current or recent acute, active infection&#xD;
&#xD;
          -  Have had a serious, chronic, recurring conditions of herpes simplex, herpes zoster,&#xD;
             recurring cellulitis, chronic osteomyelitis)&#xD;
&#xD;
          -  Have human immunodeficiency virus (HIV) infection, hepatitis B virus (HBV), hepatitis&#xD;
             C infection (HCV), active tuberculosis (TB)&#xD;
&#xD;
          -  Have active fibromyalgia or active occurrence of an inflammatory condition that, in&#xD;
             the investigator's opinion, would make it difficult to appropriately assess SLE&#xD;
             activity for the purposes of this study&#xD;
&#xD;
          -  Have experienced a cardiac event within 24 weeks to 12 months prior to screening&#xD;
&#xD;
          -  Have a history of clinically significant or uncontrolled illness that in the opinion&#xD;
             of the investigator could put the participant at risk to participate in the study&#xD;
&#xD;
          -  Are, in the judgment of the investigator, actively suicidal and therefore deemed to be&#xD;
             at significant risk for suicide&#xD;
&#xD;
          -  Are pregnant or are intending to become pregnant or to breastfeed at any time in the&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Arthritis &amp; Rheumatology Associates</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85037</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>480-626-6650</phone>
    </contact>
    <investigator>
      <last_name>Nehad Soloman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Arthritis &amp; Rheumatology Research - Sun City</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Mona Amin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christine Thai, MD</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92648</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>714-378-2440</phone>
    </contact>
    <investigator>
      <last_name>Christine Thai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Desert Medical Advances</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <zip>92260</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>760-341-6800</phone>
    </contact>
    <investigator>
      <last_name>Maria Greenwald</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ACRC Studies</name>
      <address>
        <city>Poway</city>
        <state>California</state>
        <zip>92064</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>8582270915</phone>
    </contact>
    <investigator>
      <last_name>Smitha Chiniga Reddy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida, Inc. (Clearwater)</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>727-466-0078</phone>
    </contact>
    <investigator>
      <last_name>Robert Levin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ezy Medical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>786-483-8162</phone>
    </contact>
    <investigator>
      <last_name>Hendry Perez-Pascual</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>813-870-1292</phone>
    </contact>
    <investigator>
      <last_name>Lon D. Lynn, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlanta Research Center for Rheumatology</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>770-372-3962</phone>
    </contact>
    <investigator>
      <last_name>Roel N. Querubin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Qualmedica Research, LLC</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47715</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>812-205-2475</phone>
    </contact>
    <investigator>
      <last_name>Moges Sisay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinvest Research LLC</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65810</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>4178837889</phone>
    </contact>
    <investigator>
      <last_name>David Gregory True</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>315-464-4194</phone>
    </contact>
    <investigator>
      <last_name>Andras Perl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Paramount Medical Research</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>440-826-0742</phone>
    </contact>
    <investigator>
      <last_name>Isam A Diab</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tekton Research, Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>5123885717</phone>
    </contact>
    <investigator>
      <last_name>Paul Keith Pickrell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rheumatology Center of Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
    <investigator>
      <last_name>Jacqueline D Vo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Rheumatology &amp; Arthritis Specialists</name>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <zip>77494</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <phone>281-944-3610</phone>
    </contact>
    <investigator>
      <last_name>Kiran Farheen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Privada Independencia</name>
      <address>
        <city>Munro</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
    <contact>
      <phone>5417561823</phone>
    </contact>
    <investigator>
      <last_name>ALEJANDRO JESUS ARROYO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones Clinicas Zarate</name>
      <address>
        <city>Zárate</city>
        <state>Buenos Aires</state>
        <zip>2800</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <investigator>
      <last_name>Virginia Durigan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Médicas Tucuman</name>
      <address>
        <city>San Miguel De Tucumán</city>
        <state>Tucumán</state>
        <zip>T4000AXL</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <investigator>
      <last_name>Horacio Berman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APRILLUS Asistencia e Investigacion Clinica</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1076</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <contact>
      <phone>541149512763</phone>
    </contact>
    <investigator>
      <last_name>Pablo Alejandro Mannucci Walter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DOM Centro de Reumatología</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aire</city>
        <zip>C1111</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <investigator>
      <last_name>Damaris Alvarez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CENUDIAB</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aire</city>
        <zip>C1440AAD</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <contact>
      <phone>541146820269</phone>
    </contact>
    <investigator>
      <last_name>Norma Verzero</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Revmatologie.s.r.o.</name>
      <address>
        <city>Brno</city>
        <state>Brno-město</state>
        <zip>63800</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <contact>
      <phone>00420545214556</phone>
    </contact>
    <investigator>
      <last_name>Leona Prochazkova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Artroscan, s.r.o.</name>
      <address>
        <city>Ostrava</city>
        <state>Moravskoslezský Kraj</state>
        <zip>722 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <contact>
      <phone>00420596965021</phone>
    </contact>
    <investigator>
      <last_name>Ladislav Bortlik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>779 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <contact>
      <phone>0042603449567</phone>
    </contact>
    <investigator>
      <last_name>Pavel Horak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze</name>
      <address>
        <city>Praha 2</city>
        <zip>12808</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <contact>
      <phone>00420224962696</phone>
    </contact>
    <investigator>
      <last_name>Vladimir Tesar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Medico del Angel</name>
      <address>
        <city>Mexicali</city>
        <state>Baja California</state>
        <zip>21100</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <investigator>
      <last_name>Beatriz Elena Zazueta Montiel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CIMAB SA de CV</name>
      <address>
        <city>Torreon</city>
        <state>Coahuila</state>
        <zip>27000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <contact>
      <phone>8711921259</phone>
    </contact>
    <investigator>
      <last_name>SANDRA ARACELI SICSIK AYALA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CITER Centro de Investigación y Tratamiento de las Enfermedades Reumáticas</name>
      <address>
        <city>Mexico City</city>
        <state>Distrito Federal</state>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <contact>
      <phone>5555334180</phone>
    </contact>
    <investigator>
      <last_name>Gabriel Medrano Ramirez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica de Investigacion en Reumatologia y Obesidad S. C.</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44650</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <contact>
      <phone>523331200700</phone>
    </contact>
    <investigator>
      <last_name>Sergio Duran-Barragan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinika Reumatologii i Ukladowych Chorob Tkanki Lacznej</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Kujawsko-pomorskie</state>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <phone>0048523655731</phone>
    </contact>
    <investigator>
      <last_name>Rafal Wojciechowski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Twoja Przychodnia Centrum Medyczne Nowa Sol</name>
      <address>
        <city>Nowa Sol</city>
        <state>Lubuskie</state>
        <zip>67-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <phone>0048684177519</phone>
    </contact>
    <investigator>
      <last_name>Malgorzata Miakisz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ReumaClinic</name>
      <address>
        <city>Bialystok</city>
        <state>Podlaskie</state>
        <zip>15-181</zip>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <phone>0048603995591</phone>
    </contact>
    <investigator>
      <last_name>Izabela Domyslawska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Twoja Przychodnia Poznanskie Centrum Medyczne</name>
      <address>
        <city>Poznan</city>
        <state>Wielkopolskie</state>
        <zip>61-293</zip>
        <country>Poland</country>
      </address>
    </facility>
    <contact>
      <phone>0048600334380</phone>
    </contact>
    <investigator>
      <last_name>Agata Wytyk-Nowak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Reumatologico Caguas</name>
      <address>
        <city>Caguas</city>
        <zip>00725</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <contact>
      <phone>7874471491</phone>
    </contact>
    <investigator>
      <last_name>AMARILIS J PEREZ DE JESUS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mindful Medical Research</name>
      <address>
        <city>San Juan</city>
        <zip>00918</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <investigator>
      <last_name>Oscar Soto-Raices</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Latin Clinical Trial Center</name>
      <address>
        <city>San Juan</city>
        <zip>909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <contact>
      <phone>7872494763</phone>
    </contact>
    <investigator>
      <last_name>Carlos A Pantojas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GCM Medical Group, PSC - Hato Rey Site</name>
      <address>
        <city>San Juan</city>
        <zip>917</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <contact>
      <phone>7877268396</phone>
    </contact>
    <investigator>
      <last_name>Karina Vila-Rivera</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Olla-Med</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>105554</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <contact>
      <phone>0079011808387</phone>
    </contact>
    <investigator>
      <last_name>Daria Kusevich</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Scientific Institution &quot;Research Institute Rheumatology named after V.A.Nasonova&quot;</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <contact>
      <phone>00000000000</phone>
    </contact>
    <investigator>
      <last_name>Tatyana Reshetnyak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Communal Nonprofit Enterprise of Kharkov Regional Council &quot;Regional Clinical Hospital&quot;</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkivska Oblast</state>
        <zip>61058</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <contact>
      <phone>00380500840986</phone>
    </contact>
    <investigator>
      <last_name>Svitlana Trypilka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medbud Clinic</name>
      <address>
        <city>Kyiv</city>
        <state>Kyivska Oblast</state>
        <zip>03037</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <contact>
      <phone>00380957327817</phone>
    </contact>
    <investigator>
      <last_name>Halyna Chumachenko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Edelweiss Medics</name>
      <address>
        <city>Kyiv</city>
        <state>Kyivska Oblast</state>
        <zip>2002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <contact>
      <phone>00380445949200</phone>
    </contact>
    <investigator>
      <last_name>Nataliia Boichuk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kiev City Clinical Hospital No. 3</name>
      <address>
        <city>Kiev</city>
        <state>Kyiv</state>
        <zip>2125</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <contact>
      <phone>00380442281179</phone>
    </contact>
    <investigator>
      <last_name>Oleg B. Iaremenko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center 'Modern Clinic'</name>
      <address>
        <city>Zaporizhzhya</city>
        <state>Zaporizka Oblast</state>
        <zip>69000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <contact>
      <phone>0038504216492</phone>
    </contact>
    <investigator>
      <last_name>Dmytro Rekalov</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M.I. Pyrogov Regional Clinical Hospital</name>
      <address>
        <city>Vinnytsya</city>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <contact>
      <phone>00380506986684</phone>
    </contact>
    <investigator>
      <last_name>Mykola Stanislavchuk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Czechia</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 15, 2021</verification_date>
  <study_first_submitted>November 16, 2021</study_first_submitted>
  <study_first_submitted_qc>November 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autoimmune Disease</keyword>
  <keyword>BTLA B and T Lymphocyte attenuator</keyword>
  <keyword>Immune checkpoint</keyword>
  <keyword>Inhibitory checkpoint agonist antibody</keyword>
  <keyword>Lupus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_url>http://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

